Maxcyte Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Maxcyte Inc's ROI in the second quarter of 2026?
Maxcyte Inc recorded a cumulative net loss of $-36 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -19.04%.

Within the Healthcare sector 197 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2890 to 3280.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-11.71 %	-8.91 %	-5.98 %	-6.82 %	-7.35 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	175	186	190	199	210
Return On Investment (TTM)	-19.04 %	-19.97 %	-21.87 %	-21.91 %	-21.12 %
MXCT's Overall Ranking	# 3280	# 2890	# 2986	# 3060	#
Seq. Investment Change TTM	-4.43 %	-4.03 %	-2.02 %	-1.76 %	-1.4 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-36	-39	-45	-46	-45

MXCT Company Profile >> Back to MXCT Roi Comparisons >> See Annual MXCT Return On Investment

Return On Investment MXCT's Ranking
Within:	No.
Industry	# 12
Sector	# 198
Overall	# 3280

Return On Investment Statistics
High	Average	Low
-7.21 %	-14.73 %	-21.94 %
(Mar 31 2022)		(Jun 30 2021)

News about Maxcyte inc Return on Investment ROI

MaxCyte at a Crossroads: Navigating Innovation Amidst Financial Headwinds

January 13, 2025

MaxCyte Inc.: A Legacy of Cell Engineering with Financial Challenges AheadMaxCyte, a prominent player in the biopharmaceutical landscape and a pioneer in cell engineering, recently released its preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2024. Despite two decades of innovation, the company stands at a financial crossroads, grappling with significant operational losses and a notable return on investment (ROI) that lags behind its peers in the healthcare sector.Financial Overview: Losses and GainsMaxCyte reported a cumulative net loss of $36 million for the twelve months ending September 30, 2024, reflecting a negative ROI of -15.98%. This figure is alarming, especially when juxtaposed against the performance of 252 other healthcare companies, which reported higher returns. Yet, a glimmer of hope exists: the company has shown progress in its overall ROI ranking, improving from 3076 in the second quarter to 2688 by September 30. The rising ranking may suggest a potential for recovery or investor interest as the company realigns its strategies.

MaxCyte Faces Financial Challenges as CEO Announces Retirement; Company Sets Focus on Revenue Guidance Update for 2023

December 11, 2023

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
MaxCyte Inc, a leading cell engineering company, recently announced a significant change in its management as Doug Doerfler, the current President and CEO, is set to retire effective December 31, 2023. However, Doerfler will continue to serve as an advisor to MaxCyte, ensuring a smooth transition in leadership.
The decision comes amidst challenging financial results for MaxCyte, as the company recorded a cumulative net loss of $-37 million during the 12 months ending in the third quarter of 2023. This has led to a negative return on investment (ROI) of -15.27%, raising concerns among investors and stakeholders.

Financial Statements
Maxcyte Inc's II. Quarter Investments	$ 175 Millions	MXCT's Balance sheet
Maxcyte Inc's II. Quarter Income	$ -9 Millions	Quarterly MXCT's Income Statement
MXCT's Income by Division		See MXCT's Income by Division

MXCT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	172	207	232	255	263
Y / Y Investment Growth	-16.84 %	-11.15 %	-8.95 %	-3.06 %	-
Net Income in Millions	-45	-41	-38	-24	-19
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-25.98 %	-19.88 %	-16.31 %	-9.23 %	-7.25 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Laboratories Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MXCT's Roi Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MXCT's Competitors
Subscribers only: Roi for Maxcyte Inc's Suppliers
Subscribers only: Return On Investment for MXCT's Customers

Other Ratios
MXCT's Roa	MXCT's Inventory Turnover Ratio	MXCT's Growth Rates	MXCT's Dividend Statistics
	MXCT's Profitability Ratios	MXCT's Asset Turnover Ratio	MXCT's Dividend Growth
MXCT's Roe	MXCT's Valuation Ratios	MXCT's Financial Strength Ratios	MXCT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:40:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.